Suppr超能文献

用于卵巢癌筛查的超灵敏阻抗生物传感器

Ultrasensitive Impedimetric Biosensor for Ovarian Cancer Screening.

作者信息

Gundagatti Shilpa, Srivastava Sudha

机构信息

Department of Biotechnology, Jaypee Institute of Information Technology, Noida, India.

出版信息

Indian J Microbiol. 2025 Mar;65(1):439-452. doi: 10.1007/s12088-024-01307-5. Epub 2024 May 23.

Abstract

Ovarian cancer is a significant health concern among the female vulnerable populations due to delayed diagnosis. Point-of-care devices that can be utilized for mass screening of the population may improve patient survival through early diagnosis. In this context, we report an ultrasensitive DNA-based nano-biosensor for the quantification of cancer biomarker miRNA-21 using a label-free sensing technique. Magnetite selenium ( ) nanocomposite was prepared by co-precipitation method followed by characterization using TEM, EDX, FTIR, VSM, and XRD. The average size of the nanomaterial was found to be 20 nm with a low polydispersity index of 0.2. The biosensor was fabricated by immobilizing a single-stranded DNA probe specific to miRNA-21 onto the nanocomposite modified electrode surface. At the working electrode/electrolyte interface, the binding of the DNA probe results in decreased charge transfer impedance. The developed magnetite-based impedimetric biosensor demonstrated a linear variation of resistance to charge transfer with miRNA-21 concentration (75 zM to 0.751 pM). The ultrasensitive low limits of detection (75 zM), the sensitivity of 1774.34 / g/ L/ and high selectivity over other biomarkers (miRNAs-miRNA-30e, miRNA-143, miRNA-204, DNA, protein, and cocktail of all makes it suitable for early diagnosis. Furthermore, owing to miRNA-21 prognostic as well as diagnostic value, the magnetite-based miRNA-21 impedimetric biosensor offers the promise of a sensitive consumer-centric device for mass screening of ovarian cancer.

摘要

由于诊断延迟,卵巢癌是女性易感人群中一个重大的健康问题。可用于人群大规模筛查的即时检测设备可能通过早期诊断提高患者生存率。在此背景下,我们报告了一种基于超灵敏DNA的纳米生物传感器,用于使用无标记传感技术定量检测癌症生物标志物miRNA-21。通过共沉淀法制备了磁铁矿硒( )纳米复合材料,随后使用透射电子显微镜(TEM)、能量色散X射线光谱仪(EDX)、傅里叶变换红外光谱仪(FTIR)、振动样品磁强计(VSM)和X射线衍射仪(XRD)进行表征。发现该纳米材料的平均尺寸为20纳米,多分散指数低至0.2。通过将特异于miRNA-21的单链DNA探针固定在纳米复合材料修饰的电极表面来制造生物传感器。在工作电极/电解质界面,DNA探针的结合导致电荷转移阻抗降低。所开发的基于磁铁矿的阻抗式生物传感器显示,电荷转移电阻随miRNA-21浓度(75 zeptomolar至0.751 picomolar)呈线性变化。超灵敏的低检测限(75 zeptomolar)、1774.34 / g/ L/ 的灵敏度以及对其他生物标志物(miRNAs - miRNA - 30e、miRNA - 143、miRNA - 204、DNA、蛋白质以及所有这些的混合物)的高选择性使其适用于早期诊断。此外,由于miRNA - 21的预后和诊断价值,基于磁铁矿的miRNA - 21阻抗式生物传感器有望成为一种以消费者为中心的灵敏设备,用于卵巢癌的大规模筛查。

相似文献

1
Ultrasensitive Impedimetric Biosensor for Ovarian Cancer Screening.
Indian J Microbiol. 2025 Mar;65(1):439-452. doi: 10.1007/s12088-024-01307-5. Epub 2024 May 23.
2
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
3
Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses.
Cochrane Database Syst Rev. 2016 Mar 1;3(3):CD010360. doi: 10.1002/14651858.CD010360.pub2.
5
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
6
Interventions targeted at women to encourage the uptake of cervical screening.
Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3.
7
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3.
8
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
9
Optimal primary surgical treatment for advanced epithelial ovarian cancer.
Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD007565. doi: 10.1002/14651858.CD007565.pub2.

本文引用的文献

1
Biomarkers in Cancer Detection, Diagnosis, and Prognosis.
Sensors (Basel). 2023 Dec 20;24(1):37. doi: 10.3390/s24010037.
2
MicroRNA-21 in gynecological cancers: From molecular pathogenesis to clinical significance.
Pathol Res Pract. 2023 Aug;248:154630. doi: 10.1016/j.prp.2023.154630. Epub 2023 Jun 21.
5
A novel circulating miRNA panel for non-invasive ovarian cancer diagnosis and prognosis.
Br J Cancer. 2022 Nov;127(8):1550-1556. doi: 10.1038/s41416-022-01925-0. Epub 2022 Aug 5.
6
Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study.
Cancers (Basel). 2022 Apr 29;14(9):2230. doi: 10.3390/cancers14092230.
9
Rapid electrochemical detection of MiRNA-21 facilitated by the excellent catalytic ability of Pt@CeO nanospheres.
RSC Adv. 2022 Apr 19;12(19):11867-11876. doi: 10.1039/d2ra01047j. eCollection 2022 Apr 13.
10
Development of Electrochemical Biosensor for miR204-Based Cancer Diagnosis.
Interdiscip Sci. 2022 Jun;14(2):596-606. doi: 10.1007/s12539-022-00508-0. Epub 2022 Apr 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验